BERIL-1: Biomarker results from targeted sequencing of circulating tumor DNA (ctDNA) and archival tissue in a randomized phase II study of buparlisib (BKM120) or placebo plus paclitaxel in patients ...

Association between prostate specific membrane antigen imaging and initial treatment for prostate cancer among commercial insurance beneficiaries. This is an ASCO Meeting Abstract from the 2025 ASCO ...

Approximately 20% to 30% of men with prostate cancer experience disease recurrence within 5 years of therapeutic intervention. 1 A key challenge in managing these patients is a scarcity of accurate ...

Predictions for identifying 1-year seizure recurrence performed significantly better in electroencephalography (EEG) without interictal epileptiform discharges. An automated processing algorithm ...